Bibliographic Details
| Title: |
Successful curative resection of gallbladder cancer following S-1 chemotherapy: A case report and review of the literature. |
| Authors: |
TAKAHIRO EINAMA1, KOICHIRO UCHIDA2,3, MASAHIKO TANIGUCHI2, YU OTA2, KENJI WATANABE2, KOJI IMAI2, HIDENORI KARASAKI2, ATSUSHI CHIBA4, KENSUKE OIKAWA5, NAOYUKI MIYOKAWA5, HIROYUKI FURUKAWA2 titiuehahaue@hotmail.com |
| Source: |
Oncology Letters. 2014, Vol. 8 Issue 6, p2443-2447. 5p. |
| Subject Terms: |
*GALLBLADDER cancer, *ONCOLOGIC surgery, *FLUOROURACIL |
| Abstract: |
The symptoms of gallbladder cancer (GBC) are vague and non-specific. Therefore, GBC is often detected at an advanced or metastatic stage. The most effective treatment for GBC is surgical resection, however the majority of GBC cases are unresectable at the time of diagnosis. Therefore, numerous GBC patients undergo chemotherapy. This study reports the case of a 60-year-old female with GBC who underwent successful surgical curative resection following a single dose of the chemotherapeutic agent, S-1, twice daily for 4 weeks followed by a 14-day rest period for 36 months. S-1 is a novel orally administered drug composed of a combination of the 5-fluorouracil (5-FU) prodrug, tegafur, 5-chloro-2,4- dihydroxypyridine (CDHP) and oteracil potassium in a 1:0.4:1 molar concentration ratio. The focus of the present study was the candidate factors that affect the therapeutic efficacy of S-1-based chemotherapy. In particular, the gene expression involved in the S-1 metabolic pathway was investigated by assessing the intratumoral dihydropyrimidine dehydrogenase (DPD), thymidylate synthase (TS) and orotate phosphoribosyl-transferase gene expression. The surgical specimen exhibited high intratumoral DPD gene expression levels compared with those observed in previously reported non S-1 responsive cases of biliary tract cancer. Due to the results obtained in the current study, we hypothesize that CDHP enhanced the anti- tumor efficacy of 5-FU by inhibiting the excess DPD protein produced by the tumor. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncology Letters is the property of Spandidos Publications UK Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
